Antihyperlipidemic Drugs Market Thumbnail Image

2019

Antihyperlipidemic Drugs Market

Antihyperlipidemic Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Class : Global Opportunity Analysis and Industry Forecast, 2019-2026

LS : Healthcare

Select an option
Author's: Sagar Mukhekar | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. 

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.  

Antihyperlipidemic Drugs Market

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.    

Antihyperlipidemic Drugs Market Segmentation  

The antihyperlipidemic drugs market size is studied based on segments, drug class and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the antihyperlipidemic drugs market growth include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.

Antihyperlipidemic Drugs Market
By Drug Class
Your browser does not support the canvas element.

Dialysis instrument segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

By region, North America accounted for the major antihyperlipidemic drugs market share in 2018, and is expected to continue this trend due to easy availability of the antihyperlipidemic drugs. Moreover, surge in sedentary lifestyle in the region is another major factor that contributes to the growth of the market. Furthermore, surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihyperlipidemic drugs. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

Antihyperlipidemic Drugs Market
By Region
2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 8.6% during 2019-2026.

The global antihyperlipidemic drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Key Benefits for Stakeholders:

  • This report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The antihyperlipidemic drugs market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Antihyperlipidemic Drugs Market Report Highlights

Aspects Details
icon_5
By Drug Class
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
icon_6
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_7
Key Market Players

SANOFI S.A., Amgen Inc., Merck & Co., Inc, AstraZeneca plc, Dr. Reddy’s Laboratories Ltd, ABBVIE INC., Pfizer Inc., Daiichi Sankyo Company, Limited, Mylan N.V, Bristol-Myers Squibb Company

Analyst Review

Hyperlipidemia is a medical condition, which occur due to rise in level of lipids in the blood. This leads to deposition of plaque in the arteries; thereby, narrowing them. This can also lead to blockage, which increases the risk of heath attack. The treatment of this condition involves utilization of anti-hyperlipidemic drugs. These drugs are used to control the level of lipids in the blood.

The utilization of anti-hyperlipidemic has witnessed a significant growth, owing to surge in sedentary lifestyle. Moreover, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the anti-hyperlipidemics market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, factors such as high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period

Author Name(s) : Sagar Mukhekar | Roshan Deshmukh
Frequently Asked Questions?

The total market value of antihyperlipidemic drugs market is $9456.00 million in 2018.

The forcast period for antihyperlipidemic drugs market is 2019 to 2026

The market value of antihyperlipidemic drugs market in 2019 is $10165.2 million

The base year is 2018 in antihyperlipidemic drugs market

Top companies such as, AstraZeneca plc, Pfizer Inc., Abbvie Inc., Amgen Inc., and Daiichi Sankyo Company, Limited held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.

Statins segment is the most influencing segment growing in the antihyperlipidemic drugs market owing to the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress

The key trend in the antihyperlipidemic drugs market is the rise in prevalence of hyperlipidemia across the globe which drives the growth of the market. This leads to surge in the demand for antihyperlipidemic drugs which boots the growth of the market.

Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 10.5%. This is due to surge in the awaresness related to early diagnosis and treatment of hyperlipidemia.

Antihyperlipidemic drugs are agents that promote reduction of lipid levels in the blood. Furthermore, antihyperlipidemic agents aim to lower the levels of low-density lipoprotein in the body to treat the condition called as hyperlipidemia

Antihyperlipidemic drugs are used to lower the level of bad cholestrol in the body which has the tendency to block the arteries causing variuos medical conditions such as Atherosclerosis.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Antihyperlipidemic Drugs Market

Global Opportunity Analysis and Industry Forecast, 2019-2026